-
Mashup Score: 1Phase III Trial Evaluates Routine Tranexamic Acid for Bleeding Reduction in Hematologic Malignancy | Docwire News - 19 day(s) ago
The tranexamic acid and placebo groups did not differ in occurrence of thrombotic events or veno-occlusive disease.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0FDA Approval: Treosulfan Injection With Fludarabine before Allogeneic HSCT for AML, MDS | Docwire News - 21 day(s) ago
The new indication is for use of the alkylating agent with fludarabine in a preparatory combination for allogeneic HSCT.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
Reported on #Heme Today, @US_FDA approval of #treosulfan plus #fludarabine as preparation for allogeneic #HSCT to tx #acutemyeloidleukemia, #myelodysplasticsyndromes. #AML, #MDS https://t.co/iMplevfj2R
-
-
Mashup Score: 1What Is the Link Between Gut Microbiome, Bleeding Risk in Pediatric Patients With ITP? | Docwire News - 22 day(s) ago
Gut microbiota modulates bleeding risk in pediatric patients with immune thrombocytopenia.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
Presented at #ASH24: A prospective cohort study brings insight into the relationship between gut #microbiota and bleeding risk in pediatric #immunethrombocytopenia. #ITP, #Heme https://t.co/wH5kA9iRZH
-
-
Mashup Score: 1Preliminary Data Presented on Epoetin Alfa Dose Escalation With Stable Hydroxyurea for SCD Anemia | Docwire News - 23 day(s) ago
Preliminary efficacy and safety findings from a multicenter, open-label, phase Ib/II prospective study have been encouraging.
Source: docwirenews.comCategories: General Medicine News, Oncologists1Tweet-
An ongoing prospective study by @CmulNigeria, @PittTweet has promising initial efficacy, safety data for dose escalation of #epoetinalfa plus stable #hydroxyurea for tx of #anemia in #sicklecelldisease. #SCD, #ASH24, #Heme https://t.co/hfHRJfgfFO
-
-
Mashup Score: 0FDA Grants Orphan Drug Designation to CD5-Targeting CAR T-Cell Therapy for T-Cell Lymphoma | Docwire News - 23 day(s) ago
Use is also being explored for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
New #orphandrug designation from @US_FDA --- #MB105 CD5-targeting CAR T-cell therapy for T-cell #lymphoma. Also in development for T-cell #acutelymphoblasticleukemia, #chroniclymphocyticleukemia, #mantlecelllymphoma tx use. #CLL, #MCL, #Heme https://t.co/wPBacQgp6W
-
-
Mashup Score: 0In Vitro Diagnostic Test for B-Cell Lymphomas, Plasma Cell Neoplasms Receives FDA Clearance | Docwire News - 24 day(s) ago
Clinicians can use this test to help distinguish more than 60 disease subtypes from patients’ normal immune response.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
A way to improved speed, certainty of #Bcelllymphoma, #plasmacellneoplasm dx? @US_FDA grants clearance to a single-slide, in vitro #insituhybridization assay able to distinguish more than 60 subtypes of these diseases. #BCL, #Heme https://t.co/ImIm5iIdn1
-
-
Mashup Score: 1Clinical Trial of Water-Free Orally Dissolving Anticoagulant Successfully Concludes | Docwire News - 25 day(s) ago
The new agent is on the 505(b)(2) regulatory pathway and was compared with tablet-form apixaban in 60 healthy volunteers.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
#TAH3311, a new water-free dissolving film oral anticoagulant on the #505b2 regulatory pathway, has successfully concluded its clinical trial comparing it with tablet-form #apixaban. #Heme https://t.co/E90UUwsdPg
-
-
Mashup Score: 2Kenneth Adler, MD, Reveals Drivers of Physician Burnout in Hematology, Explores Remedies | Docwire News - 27 day(s) ago
Organization-level changes at hospitals and medical groups are needed to meaningfully address this longstanding issue.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
Kenneth Adler, MD, of Morristown Medical Center in NJ, @ASH_hematology Committee on Practice, spoke with #Heme Today about the causes of physician #burnout in hematology, the institutional initiatives needed to meaningfully address it. #COVID19 https://t.co/INwcQCL4iI
-
-
Mashup Score: 1Dapsone ‘Should Be Considered’ as Pediatric ITP Treatment, Research Shows | Docwire News - 30 day(s) ago
Dapsone demonstrates efficacy and acceptable safety with low costs as treatment for pediatric ITP.
Source: docwirenews.comCategories: General Medicine News, Oncologists1Tweet-
According to a prospective cohort study presented at #ASH24, #dapsone offers good efficacy, acceptable safety, low costs as tx for pediatric #immunethrombocytopenicpurpura. #ITP, #Heme https://t.co/PZc2hlPudC
-
-
Mashup Score: 0Preliminary Data Presented on Epoetin Alfa Dose Escalation With Stable Hydroxyurea for SCD Anemia | Docwire News - 1 month(s) ago
Preliminary efficacy and safety findings from a multicenter, open-label, phase Ib/II prospective study have been encouraging.
Source: docwirenews.comCategories: General Medicine News, Oncologists1Tweet-
An ongoing prospective study by @CmulNigeria, @PittTweet has promising initial efficacy, safety data for dose escalation of #epoetinalfa plus stable #hydroxyurea for tx of #anemia in #sicklecelldisease. #SCD, #ASH24, #Heme https://t.co/hfHRJfgfFO
-
On #Heme Today, results of the phase III #TREATT trial of #tranexamicacid to reduce bleeding in pts receiving intensive tx for #hematologicmalignancy, #thrombocytopenia. Was there any difference from placebo? https://t.co/6Ap7Ee5Jpm